EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company's shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients. Regardless of this shortcoming, H.C. Wainwright believes EPKINLY will likely maintain its 2023 accelerated clearance for third-line DLBCL treatment, at least until the results of two additional ongoing Phase 3 trials are released. In this context, the firm referenced a precedent set by Roche's Columvi, which retained its accelerated approval despite missing overall survival targets in a similar patient group while expecting more study findings. Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies fo
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.MarketBeat
- Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]Yahoo! Finance
- Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]Seeking Alpha
- Genmab (GMAB)'s Future Potential Underappreciated by Market [Yahoo! Finance]Yahoo! Finance